UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/500,354	06/30/2004	Masayo Higashiyama	2004_1016A	2612

513 7590 12/20/2010

WENDEROTH, LIND & PONACK, L.L.P.
1030 15th Street, N.W.,
Suite 400 East
Washington, DC 20005-1503

EXAMINER	
FRAZIER, BARBARA S	

ART UNIT	PAPER NUMBER
1611	

NOTIFICATION DATE	DELIVERY MODE
12/20/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ddalecki@wenderoth.com
eoa@wenderoth.com

Office Action Summary	Application No.	Applicant(s)	
	10/500,354	HIGASHIYAMA, MASAYO	
	Examiner	Art Unit	
	BARBARA FRAZIER	1611	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *12 October 2010*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-10,12 and 13* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-10,12 and 13* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application
6) ☐ Other:

DETAILED ACTION

Status of Claims

1. Claims 1-10, 12, and 13 are pending in this application. Claim 11 stands canceled.

2. Claims 1-10, 12, and 13 are examined.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

4. The rejection of claims 1-10, 12, and 13 under 35 U.S.C. 103(a) as being unpatentable over Stevenson (US Patent 4,053,628) in view of Kita et al (US Patent 6,307,052) is withdrawn in view of Applicant's amendments to claims 1, 10, and 13 limiting the active ingredient to that consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid (i.e., bepotastine) or a pharmaceutically acceptable acid addition salt thereof. However, in light of and as necessitated by Applicant's amendment, a new ground of rejection is made in view of Kita et al and Lehmussaari et al (see paragraph 5, below).

5. Claims 1-10, 12, and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kita et al (US Patent 6,307,052, previously cited) in view of Lehmussaari et al (US Patent 5,795,913).

The claimed invention, as amended, is drawn to an aqueous liquid preparation comprising, in an aqueous solution, an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid (i.e., bepotastine) or a pharmaceutically acceptable acid addition salt thereof, and a water-soluble metal chloride in a light stabilizing effective amount of 0.2 w/v% or more (see claim 1).

Kita et al teach that the benzenesulfonic acid salt or benzoic acid salt of (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid (i.e., bepotastine) is excellent in antihistaminic activity and antiallergic activity, has little hygroscopicity and excellent in physicochemical stability, so that it is particularly suitable compound as a medicine. Kita et al also teach that its present invention relates to a medical composition containing the compound as an effective ingredient (see col. 1, lines 10-22).

While Kita et al teach a medical composition comprising bepotastine, Kita et al do not specifically teach how the composition is formulated, and do not specifically teach a water-soluble metal chloride in a light stabilizing effective amount of 0.2 w/v% or more.

Lehmussaari et al teach an ophthalmic composition in the form of a topical aqueous solution consisting essentially of an ophthalmologically active agent containing basic groups, an ion sensitive hydrophilic polymer containing acidic groups, and at least one salt selected from the group of inorganic salts and buffers in a total amount of from

0.01 to 2.0% by weight (abstract). The ophthalmologically active agent may be an antiallergic agent containing basic groups, including basic heterocycles, such as pyridine and piperidine (col. 4, lines 2-9). Choices of salts include sodium chloride and potassium chloride (claim 5); sodium chloride in an amount of 0.9% w/v is exemplified (col. 5, Example 2). The composition is administered as a liquid and obtains a desired beneficial effect of the active agent in the eye, while simultaneously reducing any discomfort in the patient's eye, as compared to the administration of a composition in gel form. The composition also provides for an additional wetting effect while providing for a better contact and thus a controlled absorption of active agent into the eye (col. 2, lines 10-18).

It would have been obvious to a person having ordinary skill in the art at the time the invention was made to formulate the medical composition of Kita et al with the aqueous solution of Lehmussaari et al; thus arriving at the claimed invention. One skilled in the art would be motivated to do so because the aqueous solution of Lehmussaari et al provides the benefits of better contact and controlled absorption of active agent into the eye, as well as additional wetting effect, as taught by Lehmussaari et al (col. 2, lines 10-18). One would reasonably expect success from the use of the formulation of Lehmussaari et al to formulate the medical composition of Kita et al because Lehmussaari et al teaches that the opthalmalogically active agent may be an antiallergic agent containing basic groups such as pyridine and piperidine, and Kita et al teach that it compounds have excellent antiallergic activity, and contain both pyridine and a piperidine groups.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.